CMS Proposes Repeal of Breakthrough Device Payment Pathway, Threatening Access to New Medical Tech

The Centers for Medicare and Medicaid Services (CMS) has proposed a significant policy reversal that could choke off a key funding stream for cutting-edge medical devices. The agency aims to repeal a pathway established in 2021 that allowed FDA-designated breakthrough devices to qualify for supplementary Medicare payments simply by demonstrating they are costly. This move would strip away a critical financial incentive for hospitals to adopt the latest innovations, potentially stalling patient access to new technologies.

The proposed rule would roll back a major flexibility granted to devices with the FDA's 'breakthrough' designation. Since 2001, the traditional pathway for extra Medicare payments required new devices to prove they were not only novel and expensive but also offered a 'substantial clinical improvement' over existing alternatives. The 2021 change removed that clinical improvement hurdle for breakthrough devices, making it far easier for them to secure reimbursement and, therefore, market entry. CMS's new proposal would force these devices back to the stricter, three-criteria standard, significantly raising the bar for financial support.

This regulatory shift places immediate pressure on medical device manufacturers, particularly those with products in the FDA's breakthrough pipeline or recently launched. It signals heightened scrutiny from CMS on the value and cost-effectiveness of new technologies entering the Medicare system. The change risks creating a disincentive for hospitals to invest in expensive, novel equipment if reimbursement is uncertain, potentially slowing the adoption of next-generation diagnostics and treatments for Medicare's 65 million beneficiaries. The industry now faces a critical comment period to argue against the repeal, framing it as a setback for medical innovation and timely patient care.